Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-10
DOI
10.1038/s41375-018-0261-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
- (2018) Patrick Casara et al. Oncotarget
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- GVHD and miR: good things in small packages
- (2015) J. Serody BLOOD
- The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
- (2015) T. E. Witzig et al. BLOOD
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues
- (2014) M. Wunderlich et al. BLOOD
- Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
- (2013) D. Thomas et al. BLOOD
- Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
- (2013) R. L. Thomas et al. GENES & DEVELOPMENT
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2
- (2010) A Dunkle et al. CELL DEATH AND DIFFERENTIATION
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
- (2010) M Wunderlich et al. LEUKEMIA
- Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML
- (2009) J. A. Powell et al. BLOOD
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver
- (2009) Hayato Hikita et al. HEPATOLOGY
- Synergistic drug combinations tend to improve therapeutically relevant selectivity
- (2009) Joseph Lehár et al. NATURE BIOTECHNOLOGY
- Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function
- (2008) D. A. Steimer et al. BLOOD
- Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes
- (2008) Binje Vick et al. HEPATOLOGY
- Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage
- (2008) N. Arbour et al. JOURNAL OF NEUROSCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started